| Table 14.1.1 Summary of Demographic Characteristics | |||
| Safety Population | |||
| Placebo |
Xanomeline
|
||
|---|---|---|---|
| Low Dose | High Dose | ||
| Age (years) | |||
| n | 86 | 84 | 84 |
| Mean (SD) | 75.2 (8.59) | 75.7 (8.29) | 74.4 (7.89) |
| Median (Min, Max) | 76.0 (52, 89) | 77.5 (51, 88) | 76.0 (56, 88) |
| Sex, n (%)1 | |||
| Female | 53 (61.6) | 50 (59.5) | 40 (47.6) |
| Male | 33 (38.4) | 34 (40.5) | 44 (52.4) |
| Race, n (%) | |||
| White | 78 (90.7) | 78 (92.9) | 74 (88.1) |
| Black or African American | 8 (9.3) | 6 (7.1) | 9 (10.7) |
| Other | 0 | 0 | 1 (1.2) |
| 1 Percentages are based on the number of subjects in each arm. | |||
| Source: ADSL (CDISC pilot study) | |||